2026-04-18T07:00:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1077532025-11-20T10:16:27Zcom_2072_1057col_2072_478809col_2072_478917

00925njm 22002777a 4500 dc Darbà, Josep author Ramírez, Gabriela author García-Rivero, Juan L. author Mayoralas, Sagrario author Pascual, José Francisco author Roger, Albert author Vargas, Diego author Bijedic, Adi author 2017-03-02T15:37:24Z 2017-03-02T15:37:24Z 2016-09 2017-03-02T15:37:24Z To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ... Administració de medicaments Asma Malalties pulmonars obstructives cròniques Tractament tèrmic Economia de la salut Administration of drugs Asthma Chronic obstructive pulmonary diseases Heat treatment Medical economics A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions